Impairment of hepatic uptake of rifamycin antibiotics by probenecid, and its therapeutic implications.
D000284:Administration, Oral; D000818:Animals; D001663:Bilirubin / Q000097:blood / Q000378:metabolism; D003365:Costs and Cost Analysis; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005102:Health Expenditures; D006801:Humans; D066298:In Vitro Techniques; D008099:Liver / Q000378:metabolism* / Q000503:physiopathology; D008111:Liver Function Tests; D008297:Male; D011339:Probenecid / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D051381:Rats; D012294:Rifamycins / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism*; D013448:Sulfobromophthalein; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology
D012294:Rifamycins; D013448:Sulfobromophthalein; D011339:Probenecid; D001663:Bilirubin